PURPOSE: National guidelines recommend genetic counseling and multigene germline testing (GC/MGT) for all patients with pancreatic ductal adenocarcinoma (PDAC). This study's aim was to assess real-world effectiveness of implementing systematic GC/MGT for all patients with PDAC at a high-volume academic institution. METHODS: An iterative process for systematizing GC/MGT was developed in which gastrointestinal oncology providers at the Dana-Farber Cancer Institute were recommended to refer all patients with PDAC for GC/MGT (clinician-directed referral). Workflows were subsequently changed such that patients with PDAC were automatically offered GC/MGT when scheduling their initial oncology consultation (automated referral). Clinical and germline data were collected on a consecutive cohort of patients with PDAC undergoing GC/MGT during a 25-month enrollment period (19-month clinician-directed referrals; 6-month automated referrals). RESULTS: One thousand two hundred fourteen patients with PDAC were seen for initial oncologic evaluation, 266 (21.9%) of whom underwent GC/MGT. Compared with baseline clinician-directed referrals, implementation of automated referrals led to a significant increase in patients with PDAC undergoing GC/MGT (16.5% v 38.0%, P < .001), including those undergoing multigene germline testing (MGT) ≤ 7 days of initial oncology evaluation (14.7% v 60.3%, P < .001), with preserved pathogenic variant detection rates (10.0% v 11.2%, P = 0.84). 16 of 28 (57.1%) pathogenic variant carriers had relatives who pursued cascade germline testing, and 13 of 26 (50.0%) carriers with incurable disease received targeted therapy based on MGT results. CONCLUSION: Implementation of systematic GC/MGT in patients with PDAC is feasible and leads to management changes for patients with PDAC and their families. GC/MGT workflows that bypass the need for clinician referral result in superior uptake and time to testing. Further investigation is needed to identify other barriers and facilitators of universal GC/MGT.
PURPOSE: National guidelines recommend genetic counseling and multigene germline testing (GC/MGT) for all patients with pancreatic ductal adenocarcinoma (PDAC). This study's aim was to assess real-world effectiveness of implementing systematic GC/MGT for all patients with PDAC at a high-volume academic institution. METHODS: An iterative process for systematizing GC/MGT was developed in which gastrointestinal oncology providers at the Dana-Farber Cancer Institute were recommended to refer all patients with PDAC for GC/MGT (clinician-directed referral). Workflows were subsequently changed such that patients with PDAC were automatically offered GC/MGT when scheduling their initial oncology consultation (automated referral). Clinical and germline data were collected on a consecutive cohort of patients with PDAC undergoing GC/MGT during a 25-month enrollment period (19-month clinician-directed referrals; 6-month automated referrals). RESULTS: One thousand two hundred fourteen patients with PDAC were seen for initial oncologic evaluation, 266 (21.9%) of whom underwent GC/MGT. Compared with baseline clinician-directed referrals, implementation of automated referrals led to a significant increase in patients with PDAC undergoing GC/MGT (16.5% v 38.0%, P < .001), including those undergoing multigene germline testing (MGT) ≤ 7 days of initial oncology evaluation (14.7% v 60.3%, P < .001), with preserved pathogenic variant detection rates (10.0% v 11.2%, P = 0.84). 16 of 28 (57.1%) pathogenic variant carriers had relatives who pursued cascade germline testing, and 13 of 26 (50.0%) carriers with incurable disease received targeted therapy based on MGT results. CONCLUSION: Implementation of systematic GC/MGT in patients with PDAC is feasible and leads to management changes for patients with PDAC and their families. GC/MGT workflows that bypass the need for clinician referral result in superior uptake and time to testing. Further investigation is needed to identify other barriers and facilitators of universal GC/MGT.
Authors: Uri Ladabaum; Grace Wang; Jonathan Terdiman; Amie Blanco; Miriam Kuppermann; C Richard Boland; James Ford; Elena Elkin; Kathryn A Phillips Journal: Ann Intern Med Date: 2011-07-19 Impact factor: 25.391
Authors: Maeve A Lowery; David P Kelsen; Marinela Capanu; Sloane C Smith; Jonathan W Lee; Zsofia K Stadler; Malcolm J Moore; Hedy L Kindler; Talia Golan; Amiel Segal; Hannah Maynard; Ellen Hollywood; MaryEllen Moynahan; Erin E Salo-Mullen; Richard Kinh Gian Do; Alice P Chen; Kenneth H Yu; Laura H Tang; Eileen M O'Reilly Journal: Eur J Cancer Date: 2017-12-08 Impact factor: 9.162
Authors: Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin Journal: Cancer Discov Date: 2018-06-14 Impact factor: 39.397
Authors: Ravi N Sharaf; Parvathi Myer; Christopher D Stave; Lisa C Diamond; Uri Ladabaum Journal: Clin Gastroenterol Hepatol Date: 2013-05-10 Impact factor: 11.382
Authors: Haitham W Tuffaha; Andrew Mitchell; Robyn L Ward; Luke Connelly; James R G Butler; Sarah Norris; Paul A Scuffham Journal: Genet Med Date: 2018-01-04 Impact factor: 8.822
Authors: Rachna T Shroff; Andrew Hendifar; Robert R McWilliams; Ravit Geva; Ron Epelbaum; Lindsey Rolfe; Sandra Goble; Kevin K Lin; Andrew V Biankin; Heidi Giordano; Robert H Vonderheide; Susan M Domchek Journal: JCO Precis Oncol Date: 2018-05-16
Authors: C Sloane Furniss; Matthew B Yurgelun; Chinedu Ukaegbu; Pamela E Constantinou; Catherine C Lafferty; Eliana R Talcove-Berko; Alison N Schwartz; Jill E Stopfer; Meghan Underhill-Blazey; Barbara Kenner; Scott H Nelson; Sydney Okumura; Sherman Law; Alicia Y Zhou; Tara B Coffin; Nicolette J Rodriguez; Hajime Uno; Allyson J Ocean; Florencia McAllister; Andrew M Lowy; Scott M Lippman; Alison P Klein; Lisa Madlensky; Gloria M Petersen; Judy E Garber; Michael G Goggins; Anirban Maitra; Sapna Syngal Journal: Cancer Prev Res (Phila) Date: 2021-10-08
Authors: Evan J Walker; Dena Goldberg; Kelly M Gordon; Christina Pedley; Julia Carnevale; Pelin Cinar; Eric A Collisson; Margaret A Tempero; Andrew H Ko; Amie M Blanco; Mallika Dhawan Journal: Oncologist Date: 2021-09-20
Authors: Edward D Esplin; Sarah M Nielsen; Sara L Bristow; Judy E Garber; Heather Hampel; Huma Q Rana; N Jewel Samadder; Neal D Shore; Robert L Nussbaum Journal: JCO Precis Oncol Date: 2022-09